ArticleInternational ophthalmology2025
Predictors of macular edema recurrence and visual outcomes in branch retinal vein occlusion treated with aflibercept or ranibizumab.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integration of peripheral blood-based systemic inflammatory indices and retinal imaging using interpretable machine learning for predicting anti-VEGF treatment response in macular edema secondary to retinal vein occlusion.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the risk factors for visual outcomes and recurrence of macular edema (ME) in branch retinal vein occlusion (BRVO) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents.
methodsThirty eyes of 30 patients with recent-onset, treatment naive BRVO with ME receiving IVI aflibercept and ranibizumab in a tertiary care hospital were enrolled retrospectively. Treatment response was classified into "responsive group" and "recurrent/refractory group" by absence or presence of ME after consecutive monthly IVI anti-VEGF therapy. The correlation between the optical coherent tomography and fluorescein angiography features and treatment response was analyzed during a 1-year follow-up period.
resultsIn thirty eyes, the logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.69 ± 0.39 to 0.55 ± 0.48, and was comparable in the responsive and recurrent/refractory groups (p = 0.683). At baseline, the recurrent group had a higher prevalence of subretinal fluid (SRF), disruption in the ellipsoid zone, and greater central macular thickness (CMT) than in the responsive group. Worse initial BCVA, presence of intraretinal fluid (IRF) and external limiting membrane disruption at the third month after treatment was associated with poorer final BCVA (p = 0.021, 0.014, and 0.044, respectively). Cases receiving three consecutive loading injections indicated better final BCVA (p = 0.008). Patients receiving aflibercept required fewer injections than those receiving ranibizumab (p = 0.005).
conclusionsBaseline predictors of ME recurrence included SRF presence, outer retinal layer disruptions, and greater CMT. Baseline vision, IRF at 3rd month, and the number of consecutive loading injection were correlated with visual outcomes.
Indexed as
Identifiers
40085265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.